Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials

GLP-1 receptor agonist treatment was associated with a 17% reduction in major adverse cardiovascular events (MACE).

• In seven placebo-controlled trials, GLP-1 receptor agonists showed a reduction in MACE with a Mantel-Haenszel odds ratio of 0.87.
• Cardiovascular mortality decreased with a Mantel-Haenszel odds ratio of 0.88.
• Myocardial infarction and stroke rates were also reduced, with odds ratios of 0.90 and 0.86, respectively.
• Hospitalization for heart failure did not show a statistically significant reduction, with an odds ratio of 0.93.
• The reduction in MACE was significant across various patient subgroups, including different genders, ages, and obesity levels.

AI simplified